Entera Bio Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Entera Bio Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $181.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $134.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $571.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $365.0K | Mar 8, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $33.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $198.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $65.0K | Mar 8, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.44M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.54M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.89M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($13.07M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($12.19M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.22M) | Mar 8, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.53M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.59M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.89M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($13.02M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($12.22M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.17M) | Mar 8, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.00M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.50M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $4.51M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.85M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $6.77M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.38M | Mar 8, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $398.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $340.0K | Mar 27, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.37M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($6.82M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($7.31M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($12.50M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($9.06M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($10.56M) | Mar 8, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $17.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $47.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $17.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $53.0K | Mar 8, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.99M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.39M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $11.77M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $13.13M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $25.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.72M | Mar 8, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.89M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.38M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.37M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $3.42M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.21M | Mar 8, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.10M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $8.08M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.39M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $11.75M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $22.57M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $7.51M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $13.77M | Mar 8, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($125.37M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($113.93M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($104.39M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($95.50M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($82.43M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($70.24M) | Mar 8, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.11M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $8.66M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $11.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $12.31M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $24.89M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.59M | Mar 8, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.18M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 38.84M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 35.48M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 28.81M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 28.80M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 21.06M | Mar 8, 2022 |